BioPharmSignal logoBioPharmSignal

Biotech News

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

Capricor Therapeutics (CAPR)Capricor TherapeuticsConference / presentation

CAPR (CAPR) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is capr.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

CAPRCapricor Therapeutics2026-07-29 14:05 EST

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

CAPRCapricor Therapeutics2026-06-26 14:02 EST

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

AGIOAgios Pharmaceuticals, Inc.2026-05-12 13:30 EST

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

PTCTPTC Therapeutics, Inc.2026-05-04 12:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTCTPTC Therapeutics, Inc.2026-04-28 13:28 EST

PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study

BIIBBiogen2026-07-12 15:18 EST

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

BCRXBioCryst Pharmaceuticals2026-05-13 11:00 EST

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

EDITEditas Medicine2026-05-28 20:01 EST

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

RAREUltragenyx Pharmaceutical2026-06-03 20:30 EST

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

ARWRArrowhead Pharmaceuticals2026-06-02 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

View all latest news

Capricor Therapeutics

Cell Therapy for Duchenne Muscular Dystrophy Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy. Deramiocel The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling. HOPE-3 Evidence The...

Recent company news

CAPRCapricor Therapeutics2026-07-30 13:30 EST

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

CAPRCapricor Therapeutics2026-07-29 14:05 EST

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

CAPRCapricor Therapeutics2026-07-27 15:00 EST

Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel

CAPRCapricor Therapeutics2026-06-26 14:02 EST

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

CAPRCapricor Therapeutics2026-06-26 13:05 EST

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

Stock data

Close
4.18 USD
Market cap
1.58B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States